Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 1, 2005, Pages 13-20

  Scott Stevens, Paul ^a   Atack, J R ^a   Sohal, B ^a   Worboys, P ^a,b  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

L 838417; Mice; Pharmacokinetics and receptor occupancy; Rats

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H [1,2,4]TRIAZOL 3 YLMETHOXY) [1,2,4]TRIAZOLO[4,3 B]PYRIDAZINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; FLUMAZENIL; LIGAND; RECEPTOR SUBTYPE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; IN VIVO STUDY; LIVER BLOOD FLOW; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; NONLINEAR SYSTEM; RAT; RECEPTOR OCCUPANCY; RODENT; SINGLE DRUG DOSE; SPECIES DIFFERENCE; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FLUMAZENIL; FLUOROBENZENES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, TRANSGENIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; RODENTIA; SPECIES SPECIFICITY; TRIAZOLES; TRITIUM;

EID: 13444274807     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.423     Document Type: Article

References (17)

1. A receptor subunit for benzodiazepine pharmacology. Nature 1989; 338: 582-585.
2. A receptor subtypes: Clinical efficacy and selectivity of benzodiazepine site ligands. Ann Med 1997; 29: 275-282.
3. 1 subtype. Nature Neurosci 2000; 3: 587-592.
4. Löw K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000; 290: 131-134.
5. A receptors: ligand-gated Cl ion channels modulated by multiple drug-binding sites. Trends Pharmacol Sci 1992; 13: 446.
6. Dawson GR, Tricklebank MD. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol Sci 1995; 16: 33-36.
7. Kehne JH, Cassella JV, Davis M. Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology 1988; 94: 8-13.
8. A receptor. J Neurosci 2002; 22: 5572-5580.
9. A receptor subtypes mediate the adverse interaction of benzodiazepines with ethanol? FENS Abstr 2002; 1: A142.7.
10. Möhler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002; 300: 2-8.
11. Broughton H, et al. patent WO 98/04559 1998.
12. Waynforth HB, Flecknell PA. Experimental and Surgical Technique in the Rat. Academic Press: London, 1992; 215-222.
13. 3H]Ro 15-1788. Life Sci 1985; 37: 345-355.
14. A receptors. Neuropsychopharmacology 1999; 20: 255-262.
15. Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 1980; 8 165-176.
16. Jezequel SG. Central nervous system penetration of drugs: importance of physicochemical properties. Progr Drug Metab 1992; 13: 141-178.
17. Ellinwood EH, Linnoila M, Easler ME, Molter DW. Onset of peak impairment after diazepam and after alcohol. Clin Pharmacol Ther 1981; 30: 534.